AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06432907 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: motor tasks
Description: During the study session, the patient will sit at a table in front of a computer monitor. The stereoEEG electrodes will be connected to the Neurovisor-BMM52 electroencephalograph (Medical Computer Systems, Russia) and to a computer with a software for recording and decoding brain signals (BCI classifier). One microsensor (Ascension TrekStar, Ascension Technology, USA) and two disposable cutaneous electrodes (connected to the Neurovisor-BMM52 system) will be put on each patient's hand for electromyogram recording.~The session consists from 3 blocks (1-3). The participant is asked to:~1. execute simple motor tasks (thumbs up, open hand or clench hand into fist - 30 times with each hand with 5-second brakes), according to the instruction on the computer screen;~2. to imagine the same movements - 30 times with each hand with 5-second brakes;~3. to imagine the same movements with the feedback (brain-computer interface control).~The blocks are separated by 5-minute brakes.
Study NCT05675813 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHOP+selinexor+5-Azacitidine
Description: Phase I: Patients in this arm will receive cyclophosphamide 750 mg/m² IV, doxorubicin 50 mg/m² IV, and vincristine 1.4 mg/m² IV (maximum 2 mg) on day 1, and prednisone 100 mg/day PO on days 1-5 of every 21-day cycle for the first cycle. If tumor NGS indicates T1 genetic subtype, for the remaining 5 cycles, they will receive 5-Azacitidine ih d-7-d-1 and selinexor 40mg or 60mg qw (d-7, 1, 8) by traditional 3+3 dose escalation methods and decide RP2D of selinexor.~Phase II: Patients will receive CHOP for the first cycle. If tumor NGS indicates T1 genetic subtype, then 1:1 randomized to experimental (CHOPX2) or standard CHOP regimen for 5 cycles of every 21-day cycle.
Study NCT05675813 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHOP+duvelisib+5-Azacitidine
Description: Phase I: Patients in this arm will receive cyclophosphamide 750 mg/m² IV, doxorubicin 50 mg/m² IV, and vincristine 1.4 mg/m² IV (maximum 2 mg) on day 1, and prednisone 100 mg/day PO on days 1-5 of every 21-day cycle for the first cycle. If tumor NGS indicates T2 genetic subtype, for the remaining 5 cycles, they will receive 5-Azacitidine ih d-7-d-1 and duvelisib 25mg or 50mg bid (d1-14) by traditional 3+3 dose escalation methods and decide RP2D of duvelisib.~Phase II: Patients will receive CHOP for the first cycle. If tumor NGS indicates T1 genetic subtype, then 1:1 randomized to experimental (CHOPX2) or standard CHOP regimen for 5 cycles of every 21-day cycle.
Study NCT04686825 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA-8010 2.5mg (Fasting)
Description: Test drug l : DA-8010 2.5mg (Fasting)
Study NCT04686825 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA-8010 2.5mg (Fed)
Description: Test drug ll : DA-8010 2.5mg (Fed)
Study NCT04686825 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA-8010 5mg (Fasting)
Description: Test drug llI : DA-8010 5mg (Fasting)
Study NCT04686825 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA-8010 5mg (Fed)
Description: Test drug lV : DA-8010 5mg (Fed)
Study NCT05977556 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Combined neuromuscular exercise training and 'sit less, move more' program
Description: Neuromuscular strength training: The experimental group will receive up to 24 sessions of neuromuscular strength training led by a physical therapist with expertise in geriatrics and movement behaviors. The program includes exercises such as pelvic lifts, lunges, step-ups, squats, and sit-stands. The difficulty level will progressively increase using techniques like manual resistance, dumbbells, and unstable surfaces.~Sedentary behavior intervention: The experimental group will also undergo a sedentary behavior intervention based on social cognitive theory. It involves weekly coaching sessions to enhance self-efficacy in reducing sedentary time and increasing light-intensity activity throughout the day. Participants will be provided with a wrist-worn Fitbit activity monitor for daily feedback and to track adherence to the intervention. The aim is to encourage participants to sit less and move more throughout their waking hours.
Study NCT05699525 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized MAYA Mobile App
Description: All new material in the personalized condition will be introduced within the first four weeks and will contain modules targeting participant's personal symptom profiles. The remaining two weeks in the personalized condition will consist of practicing previously learned skills.
Study NCT05699525 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: General MAYA Mobile App
Description: New material will be introduced to participants over all the six weeks of the intervention and will include all application modules.
Study NCT06224686 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional dysphagia treatment
Description: Conventional dysphagia treatment included oropharyngeal muscle movement training, orofacial alternating hot and cold stimulation, Masako swallowing training, Mendelsohn maneuver, therapeutic ingestion training, intermittent oral-esophageal tube feeding, and low-frequency electrical stimulation of swallowing neuromusculature, etc., 30 min each time, once a day for 14 consecutive days.
Study NCT06224686 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: conventional dysphagia treatment
Description: Conventional dysphagia treatment included oropharyngeal muscle movement training, orofacial alternating hot and cold stimulation, Masako swallowing training, Mendelsohn maneuver, therapeutic ingestion training, intermittent oral-esophageal tube feeding, and low-frequency electrical stimulation of swallowing neuromusculature, etc., 30 min each time, once a day for 14 consecutive days.
Study NCT06224686 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: motor imagery based on action observation treatment
Description: First, the therapist explained the purpose and principle of the intervention method to the patient, keeping the surrounding environment quiet and comfortable to avoid the patient's mood fluctuations due to external interference. Then start the treatment, the video recorded in advance was given to the patient to watch, the playback device is a ipad. The content includes lip and tongue muscle relaxation exercises, healthy people eating, chewing, swallowing, drinking and other images. At the same time, the guidance was played, which was consistent with the content in the video. The video was played 3 times consecutively for 30 min each time, once a day for 14 days.
Study NCT05675813 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHOP+chidamide+tislelizumab
Description: Phase I: Patients in this arm will receive cyclophosphamide 750 mg/m² IV, doxorubicin 50 mg/m² IV, and vincristine 1.4 mg/m² IV (maximum 2 mg) on day 1, and prednisone 100 mg/day PO on days 1-5 of every 21-day cycle for the first cycle. If tumor NGS indicates T3 genetic subtype, for the remaining 5 cycles, they will receive tislelizumab 200mg d0 ivgtt and chidamide 20mg or 30mg biw (d1,4,8,11) by traditional 3+3 dose escalation methods and decide RP2D of chidamide.~Phase II: Patients will receive CHOP for the first cycle. If tumor NGS indicates T3 genetic subtype, then 1:1 randomized to experimental (CHOPX2) or standard CHOP regimen for 5 cycles of every 21-day cycle.
Study NCT06088745 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Herpes Zoster Vaccine
Description: The active ingredient of the recombinant herpes zoster vaccine is varicella-zoster virus glycoprotein E fusion protein expressed in CHO cells by gene recombination technology. The LZ901 cell line carrying this gene is cultured in chemically defined medium. The harvest cell culture is purified by multi-step liquid chromatography. After Low pH incubation and virus removal filter package Nanofiltration inactivation/virus removal process, the bulk containing high-purity recombinant herpes zoster virus glycoprotein E is obtained. Finally, an alumina adjuvant is added to the formulated final product.
Study NCT06088745 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Recombinant Herpes Zoster Vaccine Placebo
Description: Alumina adjuvant
Study NCT05675813 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: standard CHOP
Description: Patients in this arm will receive cyclophosphamide 750 mg/m² IV, doxorubicin 50 mg/m² IV, and vincristine 1.4 mg/m² IV (maximum 2 mg) on day 1, and prednisone 100 mg/day PO on days 1-5 of every 21-day cycle for the 6 cycles.
Study NCT05884489 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: A gamified smartphone app-based eating behaviour intervention
Description: All patients gained access to the healthy nutrition application and were encouraged to make full use of its feature, and they were also required to maintain a logbook through the application at home to follow-up on their diet. The intervention last for six weeks.
Study NCT05125926 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LYB001
Description: The investigational vaccine, with its antigen consisting of receptor-binding domain (RBD) from SARS-CoV-2 and virus-like particle (VLP) vector, adjuvanted with aluminum hydroxide. The investigational are administered through Intramuscular injection (IM) at upper arm deltoid on day 0, 28, 56.
Study NCT05125926 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Aluminum hydroxide
Study NCT05761340 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Helfer skin tap injection technique
Description: 1. Place the patient in a seated position and open his right arm to inject into the deltoid muscle.~2. After determining the injection site, use the tips of the dominant hand fingers to hit the skin (about 15 strokes) for about five seconds to soften the muscles.~3. After cleaning the skin with alcohol, remove the syringe cover from the dominant hand. Make a V with the non-dominant hand and hit the skin three times.~4. During the third stroke, prick the syringe into the muscle at 90 degrees angle at the same time.~5. After aspiration, continue to hit the skin with the tips of the non-dominant hand fingers while injecting the drug with the dominant hand at a rate of 1 ml / 10 seconds.~6. After injecting the drug, make the non-dominant hand V-shaped and hit the skin three times, pulling the syringe needle out at the same time during the third stroke
Study NCT05761340 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Standard Injection technique
Description: 1. Place the patient in a seated position and open his right arm to inject into the deltoid muscle area.~2. After determining the injection site, prepare the skin with alcohol.~3. Grasp the skin with the thumb and index finger of the non-dominant hand and prick the syringe into the muscle at a 90-degree angle.~4. After aspiration, inject the drug with the dominant hand at a rate of 1 ml /10 seconds.~5. Remove the syringe needle 10 seconds after the drug is consumed
Study NCT05722639 — intervention group
Intervention type: DEVICE
Intervention: X-Trodes acquisition system
Description: No intervention. The participants will sit passively while electrophysiology signals are captured from two devices in order to evaluate the signal quality.
Study NCT05884775 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mobile Health (mHealth) Patient-Reported Outcome (PRO) tool
Description: Once the program begins, the AI chatbot sends daily text messages that include the PRO questions; a link to a library of educational resources tailored to their responses and personalized motivational messages with support. Participants will also be sent links to the interactive web-based dashboard that visualizes their daily PRO and HbA1c data. PCPs will be able to view reports of patients' PRO and home A1c data through the EHR interface, which can be reviewed during visits with the patient or asynchronously to track patient PROs between visits.
Study NCT05415800 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Quality Improvement Practice Facilitation Intervention
Description: The practice facilitation intervention (implementation strategy package) consists of QI projects designed for primary care providers with external practice facilitation and technical support provided by a QI Coach and Data Coach on our team.~The QI projects focus on the implementation of cancer prevention and early detection guidelines in primary care settings, specifically one QI project for each of the following clinical guidelines: colorectal cancer screening, lung cancer screening, and tobacco treatment. The study participants are the healthcare providers and staff, not the patients, since the goal of the practice facilitation intervention (implementation strategy package) is to improve the implementation of existing standard of care.
Study NCT06295770 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Obinutuzumab 1g IV on day one and 1 g IV on day 15, followed by identical course at month 6.
Study NCT04721639 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sphinx Yoga Therapy
Description: Sphinx Pose Yoga is among the best beginner Yoga Poses that relieve Lower Back Pain. It extends the back gently and activates muscles along the spine. The subject will be asked to lay down on their stomach with feet set hip-width apart, the elbows positioned under the shoulders, and the legs held together. The chin should be pointing towards the floor. Next, the subject is required to pull up the kneecaps, squeezing the thighs and buttocks, pressing the pubic bone into the floor and dropping shoulders back away from the neck and pushing the chest forward. In this position, the subject is asked to breathe and hold the pose for two to six breaths. By the end, the subject will be required to exhale, bringing the elbows to the sides and slowly lowering the chest and head to the floor.
Study NCT04646811 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tricuspid valve
Description: Clip for the tricuspid valve implantation on top of best medical therapy
Study NCT04646811 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Best medical treatment
Description: Best medical therapy alone
Study NCT05659303 — intervention group
Intervention type: PROCEDURE
Intervention: Laparoscopic hysterectomy
Description: Patient having undergone a hysterectomy, planned as an outpatient during the pre-operative consultation, by laparoscopic route.
Study NCT04786405 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness meditation
Description: Participants in the mindfulness meditation condition will practice a breath and body focused meditation.
Study NCT04786405 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Clinical hypnosis
Description: Participants in clinical hypnosis will be guided in a hypnosis practice with suggestions tailored towards shifting pain appraisals.
Study NCT06784622 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment as usual
Description: Well-Root PT is clinically used in many areas such as pulp capping, perforation and resorption repair, root tip filling and apexification. As Well-Root PT is available in pre-mixed capsule form, it can provide a consistent and adequate consistency and clinical convenience. Well-Root PT can be applied directly into the oral cavity by placing the capsule in a syringe. In addition, Well-Root PT has a shorter setting time than MTA.Despite these advantages, there is no study in the literature on the effect of Well-Root PT on postoperative pain and tooth vitality after pulpotomy in mature permanent molars
Study NCT06782763 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Repetitive transcranial magnetic stimulation device
Description: Activating neurons: rTMS can activate or inhibit neuronal activity in certain brain areas, changing the activity pattern of neural networks. Neuroplasticity: By changing the strength and connection mode of synapses, it promotes the plasticity of the nervous system, which helps treat neuropsychiatric diseases. Regulating neurotransmitters: rTMS can regulate the release of neurotransmitters, affect nerve conduction, and thus improve disease symptoms.
Study NCT06782763 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Repetitive transcranial magnetic stimulation device
Description: Activating neurons: rTMS can activate or inhibit neuronal activity in certain brain areas, changing the activity pattern of neural networks. Neuroplasticity: By changing the strength and connection mode of synapses, it promotes the plasticity of the nervous system, which helps treat neuropsychiatric diseases. Regulating neurotransmitters: rTMS can regulate the release of neurotransmitters, affect nerve conduction, and thus improve disease symptoms.
Study NCT05470595 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab (IMP) will be added to Platinum/Etoposide (Standard-of-Care). Four cycles of combined immunochemotherapy 3qw will be follows by maintenance with atezolizumab monotherapy until progression.
Study NCT06786416 — intervention group
Intervention type: OTHER
Intervention: PEQUOD
Description: During cardiopulmonary bypass registration of the parameters of interest by the Livanova BE-CAPTA monitor. After surgery, registration of creatinine values up to 48 postoperative hours.
Study NCT06787313 — intervention group
Intervention type: OTHER
Intervention: precision palliative care
Description: Participants receive precision palliative care based on scale screening result.
Study NCT06784271 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Phenylcapsaicin
Description: 2.5mg of Phenylcapsaicin
Study NCT06784271 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT06788145 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social Support Single-Session Intervention
Description: Single-session intervention to increase self-efficacy, social support, help-seeking, and recovery-oriented behaviors to address disordered eating.
Study NCT05661942 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcium pre-treatment
Description: The intervention is Calcium gluconate 1 gram/100ml 0.9% NaCl or 100ml 0.9% NaCl) over 5 minutes.
Study NCT05661942 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo/ no calcium pre-treatment.
Study NCT05198934 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sotorasib
Description: Sotorasib will be administered orally
Study NCT05198934 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panitumumab
Description: Panitumumab will be administered as intravenous (IV) infusion
Study NCT05198934 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trifluridine and Tipiracil
Description: Trifluridine and Tipiracil will be administered orally
Study NCT05198934 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Regorafenib
Description: Regorafenib will be administered orally
Study NCT05389553 — intervention group
Intervention type: OTHER
Intervention: Ultrasound exam
Description: We included all full-term pregnancies accepted for delivery that received an accurate ultrasound scan before the birth
Study NCT05206747 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Blue-blocking glasses
Description: It will transmit 45% of visible light with the following light transmission profile.
Study NCT05206747 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Lightly-tinted glasses
Description: It will also filter short wavelength light but at a lower threshold with near identical transmission above this threshold. It will transmit 91% of visible light with the following light transmission profile.
Study NCT05481658 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diphencyprone (DPCP)
Description: topical immunomodulator
Study NCT05281718 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Factor IX
Description: Factor IX is on of the substrates of emicizumab.
Study NCT06366451 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rilvegostomig
Description: Intratumoral microdose injection by the CIVO device.
Study NCT06366451 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Volrustomig
Description: Intratumoral microdose injection by the CIVO device.
Study NCT06366451 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sabestomig
Description: Intratumoral microdose injection by the CIVO device.
Study NCT06366451 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AZD9592
Description: Intratumoral microdose injection by the CIVO device.
Study NCT06366451 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Intratumoral microdose injection by the CIVO device.
Study NCT06366451 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: AZD9592 + Rilvegostomig
Description: Intratumoral microdose injection by the CIVO device.
Study NCT06366451 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: AZD9592 + Volrustomig
Description: Intratumoral microdose injection by the CIVO device.
Study NCT06366451 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: AZD9592 + Sabestomig
Description: Intratumoral microdose injection by the CIVO device.
Study NCT06366451 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: AZD9592 + Pembrolizumab
Description: Intratumoral microdose injection by the CIVO device.
Study NCT05540938 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Wangbi granules
Description: Methotrexate 7.5-15mg qw plus tofacitab 5mg bid, combined with Wangbi granules 12.0g tid, treatment course 3 months.
Study NCT05540938 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Wangbi granules simulant
Description: Methotrexate 7.5-15mg qw plus tofacitab 5mg bid, combined with Wangbi granules simulant 12.0g tid, treatment course 3 months.
Study NCT06418321 — intervention group
Intervention type: DEVICE
Intervention: Investigational device
Description: The participants' hearing status will be evaluated using the investigational device.